DUBLIN--(BUSINESS WIRE)--The "Europe Market Report Suite for Immunology Drugs 2017 - MedSuite" report has been added to ResearchAndMarkets.com's offering.
Besides the typical market data found above you will be able to discover how these diseases have been trending over time, their epidemiology, drivers and limiters of these markets, Porter's Five Forces analysis, clinical trials, a pipeline of products coming out soon, mergers and acquisitions, company profiles and SWOT analyses.
Key Topics Covered:
Clinical Trials Overview
Promising new drugs for Ankylosing Spondylitis in the pipeline
Promising new drugs for Crohn's Disease in the pipeline
Promising new drugs for Psoriasis in the pipeline
Promising new drugs for Rheumatoid Arthritis in the pipeline
Key Marketed Products Portfolio
Remicade (infliximab) + Remsima/Inflectra (infliximab)
Drug Cost Analysis
Europe Immunology Market Overview
Currency Exchange Rate
Europe Immunology Market - By Diseases
Europe Immunology Market - By Treatments
Biologics (Biologic DMARDS)
Non-biologics (corticosteroids, NSAIDs, tDMARDS & other non-biologic)
Europe Immunology Biologics Segment Analysis - By Drugs
Rheumatoid Arthritis Drugs
Crohn's Disease Drugs
Ankylosing Spondylitis Drugs
Ulcerative Colitis Drugs
Europe Immunology Biologics Segment Analysis - By Mechanism Of Action (MOA)
Rest of Europe
Mergers & Acquisitions
Collaborations & Agreements
Market Shares & Competitive Analysis - by key players
- AbbVie Inc.
- AstraZeneca Plc
- F. Hoffmann-La Roche Ltd
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Pfizer Inc.
- Takeda Pharmaceuticals
- UCB S.A.
For more information about this report visit https://www.researchandmarkets.com/research/hwsz5v/europe_immunology?w=4